Montreal and Berlin-based Reliant AI, a startup focused on leveraging AI to enhance data processing in the biopharma industry, has officially come out of stealth mode, announcing the successful close of a $15.4 million CAD seed funding round.
The round was co-led by Inovia Capital and Tola Capital, with additional backing from prominent investors, including former Cisco chief strategy officer Mike Volpi and AI pioneer Yoshua Bengio.
Leveraging AI for Biopharma Data Analysis
Founded by Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel—former senior research scientists at Google DeepMind—Reliant AI is developing an AI-driven data analytics platform specifically for the biopharmaceutical sector. Their first product, Reliant Tabular, is designed to help life science analysts quickly and accurately find scientific evidence through automated reviews and data analysis. The platform is tailored to meet the complex needs of biopharma researchers, enabling them to perform asset scans nearly five times faster than traditional methods and with significantly fewer errors.
Advertisement
Strategic Growth and Future Plans
With the fresh capital, Reliant AI plans to expand its engineering team and increase its presence across Europe and North America. The startup is also focused on scaling its AI technology to meet the growing demands of the pharmaceutical industry, as companies look to innovative solutions to streamline research and development processes.
Reliant AI’s decision to invest in its own AI hardware rather than rely on larger providers underscores its commitment to building robust, scalable technology. The company is currently offering demos of its product and working with select partners, with plans to expand its customer base significantly by the end of the year.
The seed funding marks a pivotal moment for Reliant AI as it positions itself to make a substantial impact on the biopharma industry, using AI to transform how data is processed and analyzed in this critical field.
